The goal of the Protocol Review and Monitoring System (PRMS) is to provide scientific oversight of cancer clinical trials conducted at City of Hope Comprehensive Cancer Center independent of the protection of human subjects afforded through the COM Institutional Review Board (IRB). This function is organized around the Cancer Center's Cancer Protocol Review and Monitoring Committee (CPRMC). City of Hope supports an internal Cancer Protocol Review and Monitoring Committee (CPRMC) to: 1) maintain the high quality of institutional clinical research;2) prioritize clinical research conducted by Cancer Center members; 3) provide a pathway for innovative clinical protocol research in the diagnosis, therapy, prevention and control of cancer to gain full access to shared resources and services supported by the Cancer Center Support Grant (CCSG). Scientific review requiring full committee vote is required for all new trials, amendments to on-going trials, and continuing trials?the latter on a yearly basis. The scientific review for new trials includes an evaluation of study design, scientific rationale, potential for accrual and biostatistical input for all new studies. Review of annual continuations includes an examination of actual accrual. Investigator-initiated Cancer Center-supported clinical protocols cannot have access to any of the Center's core facilities without full approval of the study by the CPRMC. Data and safety monitoring is conducted in compliance with the NCI-approved Data and Safety Monitoring Plan for Cancer Clinical Trials. This level of review provides an independent means of confirming the efficacy of the investigational treatment programs ongoing in the Cancer Center. The total annual budget of the CPRMC is $125,483 of which the institution pays 52% and CCSG funding is requested for $ 60,819, or 48% of the total. Total staffing for the core is 2.99 FTEs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-29
Application #
8374908
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-04-24
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
29
Fiscal Year
2012
Total Cost
$81,771
Indirect Cost
$44,621
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Mendez-Dorantes, Carlos; Bhargava, Ragini; Stark, Jeremy M (2018) Repeat-mediated deletions can be induced by a chromosomal break far from a repeat, but multiple pathways suppress such rearrangements. Genes Dev 32:524-536
Bzymek, Krzysztof P; Puckett, James W; Zer, Cindy et al. (2018) Mechanically interlocked functionalization of monoclonal antibodies. Nat Commun 9:1580
Nguyen, Huong Q; Ruel, Nora; Macias, Mayra et al. (2018) Translation and Evaluation of a Lung Cancer, Palliative Care Intervention for Community Practice. J Pain Symptom Manage 56:709-718
Satheesan, Sangeetha; Li, Haitang; Burnett, John C et al. (2018) HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. J Virol 92:
Zhang, Jing; He, Zhiheng; Sen, Subha et al. (2018) TCF-1 Inhibits IL-17 Gene Expression To Restrain Th17 Immunity in a Stage-Specific Manner. J Immunol 200:3397-3406
Sun, Jie; He, Xin; Zhu, Yinghui et al. (2018) SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function. Cell Stem Cell 23:355-369.e9
Miao, Yifei; Ajami, Nassim E; Huang, Tse-Shun et al. (2018) Enhancer-associated long non-coding RNA LEENE regulates endothelial nitric oxide synthase and endothelial function. Nat Commun 9:292
Sen, Subha; Wang, Fei; Zhang, Jing et al. (2018) SRC1 promotes Th17 differentiation by overriding Foxp3 suppression to stimulate ROR?t activity in a PKC-?-dependent manner. Proc Natl Acad Sci U S A 115:E458-E467
Murad, John P; Kozlowska, Anna K; Lee, Hee Jun et al. (2018) Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. Front Immunol 9:2268
Brown, Christine E; Aguilar, Brenda; Starr, Renate et al. (2018) Optimization of IL13R?2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Mol Ther 26:31-44

Showing the most recent 10 out of 1396 publications